Market Update: Regeneron, UPS, and Zebra
Regeneron (REGN) has seemingly overcome its bear phase, with shares rebounding by 12% to over $650 after hitting a bottom of $550-$575.
The company reported a 0.8% increase in revenue to $3.75 billion, driven by strong sales of Dupixent, which reached $4.9 billion. This offset weak sales from EYLEA, although EYLEA HD sales grew by 42% to $663 million.
- Regeneron's revenue increased by 0.8% to $3.75 billion.
- Dupixent sales reached $4.9 billion.
- EYLEA HD sales grew by 42% to $663 million.
UPS, despite being down 25% in 2025, added 8.0% after posting non-GAAP EPS of $1.74 on revenue of $21.4 billion, a 3.6% year-over-year decrease. The company announced a significant 48,000 job cut, with 34,000 cuts in the operational unit and 14,000 at the management level.
The stock markets rallied after the firm announced the massive job cut.
Zebra (ZBRA) continued its downtrend, which began in August and accelerated in October, with the stock losing 11%.
Author's summary: Stocks show mixed results amid earnings reports.
More News
- Coats Group completes acquisition of OrthoLite, restructures divisions
- Intuition and AI - Vital Role - I by IMD
- Will ARC Raiders Survive? A Deep Dive Into Its Future | Invision Game Community
- Dutch election: D66 and PVV neck and neck with smallest difference ever
- 'Secretly they continue to live within us and through us' – Baptist News Global
- CXMT begins producing advanced LPDDR5X memory chips as China narrows tech gap
- Austin Reaves cracks viral joke after buzzer-beater lifts Lakers to win
- Anti-VEGF innovations in retinal disease: From molecules to medicine | Ophthalmology Times - Clinical Insights for Eye Specialists